Article

Juvenile Diabetes Is on the Rise

Author(s):

Pediatric diabetes and kidney complications related to it are on the rise, a new analysis of insurance data shows.

The annual prevalence of pediatric diabetes and pediatric diabetic nephropathy “markedly increased starting at age 12 years,” a new analysis of insurance data shows. The results were published online ahead of print on December 17, 2015, and appear in the February 2016 issue of Diabetes Care.

A team lead by Lin Li, MD, PhD, Research Assistant Professor of Epidemiology, Boston Collective Drug Surveillance Program, Boston University School of Public Health in Lexington MA, in conjunction with researchers at Bayer Pharma AG in Germany, estimated the prevalence of diabetes and diabetic nephropathy in U.S. commercially insured patients under age 18. They used the U.S. MarketScan Commercial Claims and Encounters Database to identify 96,171 pediatric patients with diabetes and 3,161 children with diabetic nephropathy between 2002 and 2014. From this sample, they estimated the prevalence of pediatric diabetes and diabetic nephropathy in the U.S. population.

The annual prevalence of pediatric diabetes had increased from 1.86 to 2.82 per 1,000 during the period measured. The prevalence of type 1 diabetes went up from 1.48 to 2.32 per 1,000, while type 2 increased from 0.38 to 0.67 per thousand.

Diabetic nephropathy tripled from 1.16 to 3.44 percent for all cases. Prevalence was highest among patients between 12 and 18 years. Type 1 diabetes prevalence was higher in boys, while type 2 diabetes and diabetic nephropathy was higher in girls.

Related Videos
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
Jennifer B. Green, MD: Implementation of Evidence-Based Therapies for T2D | Image Credit: Duke University
Ralph A. DeFronzo, MD: Noxious Nine and Mifepristone for Hypercortisolism in T2D | Image Credit: LinkedIn
Diabetes Dialogue: Diabetes Tech Updates from November 2024 | Image Credit: HCPLive
Viet Le, DMSc, PA-C | Credit: APAC
Diabetes Dialogue: Tirzepatide’s Long-Term Obesity Data | Image Credit: HCPLive
Diabetes Dialogue: Latest Updates on Semaglutide Shortage, Data | Image Credit: HCPLive
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
© 2024 MJH Life Sciences

All rights reserved.